James D Chalmers
@ProfJDChalmers
Followers
9K
Following
26K
Media
826
Statuses
6K
Asthma and Lung UK Chair of Respiratory Research, University of Dundee. Chief Editor of the European Respiratory Journal. Tweets in a personal capacity
Dundee, UK
Joined July 2019
This was a challenging trial to conduct and a huge team effort - thanks to Tayside Clinical Trials Unit @TASC_TCTU all of our collaborating centres and participants.
0
0
4
Just published @ERSpublications .The MUSIC trial.COPD patients randomized to fluticasone/salmterol (FS), compared with budesonide, had an increase in sputum bacterial load over 3 months.Inhaled corticosteroid withdrawal was poorly tolerated in severe COPD.
3
13
44
I look very happy about the ASPEN trial results 🤣.
🚨 Last week, the FDA approved #brensocatib (Brinsupri; Insmed)—the first therapy for non–CF bronchiectasis and the first DPP1 inhibitor approved for a neutrophil-mediated disease. Dr James Chalmers discusses the ASPEN trial and its impact on care.
1
2
35
RT @ATS_PITB: 🚨 New 2025 ATS guidelines on community-acquired pneumonia! Key changes:. Lung ultrasound now an evidence-based alternative to….
0
7
0
RT @EuropeanLung: ELF worked with EMBARC to create a new resource designed to help people living with bronchiectasis feel more informed, co….
0
10
0
RT @EuropeanLung: 💡 Help shape the future of bronchiectasis care by completing the ‘Untold Stories of Bronchiectasis’ survey. ELF has par….
0
1
0
RT @lifearc1: At 61, Gaynor Hardman was diagnosed with bronchiectasis, an overlooked and misunderstood chronic respiratory disease. It wasn….
0
2
0
RT @EuroRespSoc: 📄 A new ERS and @atscommunity statement – ‘Update of the International Multidisciplinary Classification of the Interstitia….
0
19
0
RT @BTSrespiratory: The awards presented at our Winter Meeting were created as an opportunity to celebrate impactful individuals within our….
0
2
0
RT @DrMMukherjee: A benchmark for translational research! 💯 congratulations @MereteLong @ProfJDChalmers.
0
2
0
🚨Just published!🚨.Perfect timing with FDA approval of brensocatib in bronchiectasis.An in-depth investigation into how DPP1 inhibitors affect neutrophils showing novel and potentially beneficial effects on azurocidin1 and receptor expression @MereteLong .
jacionline.org
Dipeptidyl peptidase-1 (DPP-1/Cathepsin C) processes and activates neutrophil serine proteases. Brensocatib (an oral, reversible, competitive DPP-1 inhibitor) is a novel therapy for bronchiectasis...
2
22
66
RT @YCGaryLee: Prof Chotirmall @NTUsg: overview to changes in thinking of #bronchiectasis at #Malaysian #Thoracic Soc. Not one end diseas….
0
5
0
RT @lifearc1: Our partners can benefit from:. ✅ Funding and investment.✅ Personalised strategic advice.✅ Industrial know-how to develop ind….
0
1
0
RT @ATS_PITB: FDA approves brensocatib for the tx of bronchiectasis: ". [o]nce-daily tx with brensocatib. led to….
nejm.org
In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP...
0
8
0
RT @ATS_AII: 🚨🚨🚨Breaking News🚨🚨🚨.Brensocatib has become FDA-approved for the treatment of bronchiectasis!
0
40
0
RT @NatRevDrugDisc: Neutrophil-targeted drug brensocatib secures first FDA approval for inflammatory lung disease .
0
21
0
Check out the new ATS guidelines for community-acquired pneumonia 👇.
✨NEW✨ATS Guidelines for Community-Acquired Pneumonia-addresses lung ultrasound for diagnosis, empiric antibacterial therapy if a test for a respiratory virus is positive, antibiotic duration, and the use of systemic corticosteroids.
0
7
15
Just published online in the Blue Journal - we show that inconsistency in trial results for inhaled antibiotics are likely due to big differences in the microbiome between regions and groups of patients. It isn't just about Pseudomonas, but also the surrounding microbiome!.
Endotypes of Pseudomonas aeruginosa Infection in Bronchiectasis Are Associated with Inhaled Antibiotic Response: Results from Two Randomized, Double-Blind, Placebo-controlled Phase III Trials (ORBIT 3 and ORBIT 4).@ProfJDChalmers .@beccahull_ . 🔗
0
9
43
So proud of the brilliant Rebecca Hull PhD, highlighted this month as an emerging investigator in the Blue Journal for her work on host-pathogen interactions in bronchiectasis.👏👏👏.
The Blue Journal thanks Rebecca Hull, PhD, for her contribution to the August issue. Endotypes of Pseudomonas aeruginosa Infection in Bronchiectasis Are Associated with Inhaled Antibiotic Response .@beccahull_ .@ProfJDChalmers .@dundeeuni .
2
5
29